Researchers have assessed the ability of the calcium mimetic cinacalcet to reduce the levels of serum calcium in patients with intractable primary hyperparathyroidism and serum calcium levels >3.1 mmol/l. Can clinicians finally control hypercalcemia in patients with intractable primary hyperparathyroidism?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hasse, C. et al. Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results. World J. Surg. 26, 1029–1036 (2002).
Hedbäck, G. & Odén, A. Recurrence of hyperparathyroidism: a long-term follow-up after surgery for primary hyperparathyroidism. Eur. J. Endocrinol. 148, 413–421 (2003).
Marcocci, C. et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2766–2772 (2009).
Bilezikian, J. P. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009).
Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1–S130 (2009).
Brown, E. M. Calcium receptor and regulation of parathyroid hormone secretion. Rev. Endocr. Metab. Disord. 1, 307–315 (2000).
Khan, A., Grey, A. & Shoback, D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94, 373–381 (2009).
Peacock, M. et al. Cinacalcet hydrochloride maintains long-term normocalcaemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90, 135–141 (2005).
Peacock, M. et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. doi:jc.2009-1472v1.
De Francisco, A. L. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin. Pharmacother. 9, 795–811 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. L. M. de Francisco declares an association with the following companies: Amgen (consultant, speaker), Shire (consultant, speaker), Roche (consultant, speaker). C. Piñera declares no competing interests.
Rights and permissions
About this article
Cite this article
de Francisco, A., Piñera, C. Cinacalcet—can it control hypercalcemia?. Nat Rev Endocrinol 6, 15–17 (2010). https://doi.org/10.1038/nrendo.2009.245
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.245
